Diane M Larson, LCSW Clinical Social Worker Medicare: Accepting Medicare Assignments Practice Location: 14144 Nephron Ln, Hudson, FL 34667 Phone: 727-251-3832 Fax: 727-251-3832 |
Hannah Ganskop, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 13707 Sewell Ln, Hudson, FL 34667 Phone: 507-244-1393 |
Patricia Coyle, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 12405 Spanish Moss Dr, Hudson, FL 34667 Phone: 352-678-2353 |
Heather Kristen Flowers, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 7453 Mako Dr, Hudson, FL 34667 Phone: 813-943-6033 |
Brianna Karee Rose Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 12801 Freeboard Ct, Hudson, FL 34667 Phone: 813-743-2888 |
Amanda Sipiczky Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 12518 Chenwood Ave, Hudson, FL 34669 Phone: 727-485-7438 |
Mrs. Melva Rita Milios, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 12000 Us Highway 19, Suite F, Hudson, FL 34667 Phone: 727-860-5675 Fax: 727-860-5675 |
Jennifer A Weber, LCSW Clinical Social Worker Medicare: Accepting Medicare Assignments Practice Location: 8224 State Rd 52, Hudson, FL 34667 Phone: 352-212-9949 |
News Archive
Mylan Inc. has announced that its subsidiary Mylan Pharmaceuticals Inc. has received approval from the U.S. Food and Drug Administration (FDA) for its supplemental Abbreviated New Drug Application (ANDA) for Haloperidol Tablets USP, 10 mg and 20 mg. These strengths are in addition to Mylan's currently marketed 0.5 mg, 1 mg, 2 mg and 5 mg strengths of the product.
Mylan Inc. today announced the U.S. launch of its Norethindrone Acetate and Ethinyl Estradiol Tablets USP, 1 mg/0.02 mg and Ferrous Fumarate, which is the generic version of Warner Chilcott's Loestrin 24 Fe.
Patients undergoing total hip replacement experience meaningful and lasting improvements in quality of life (QOL) through at least five years after the procedure, reports a study in the March 15 issue of The Journal of Bone & Joint Surgery. The journal is published by Wolters Kluwer.
A team of researchers at the Icahn School of Medicine at Mount Sinai, in collaboration with GenScript, is developing a synthetic antibody to SARS-CoV-2, the virus that causes coronavirus disease (COVID-19). This antibody is intended to block the virus from entering human lung cells, and would be another potential treatment option for COVID-19.
A federal judge will rule by the end of the year on a Virginia challenge to the federal health law provision requiring people to buy insurance, The New York Times reports.
› Verified 7 days ago